How Anand Tharmaratnam Became CEO of Novotech
By Sreekanth, US-based NRI Journalist
In the high-stakes world of clinical research organizations (CROs), where precision, speed, and global reach determine the pace of life-saving therapies, few leaders embody decades of expertise and forward momentum like Dr. Anand Kumaresh Tharmaratnam. On January 1, 2026, he assumed the role of Chief Executive Officer and Chairman at Novotech, a leading full-service biotech CRO renowned for partnering with innovative biotech and mid-sized pharma companies. With over 30 years in the global CRO and life sciences industry—including a transformative 23-year tenure at Quintiles (later IQVIA)—Dr. Tharmaratnam’s appointment marks a pivotal chapter for Novotech as it expands its international footprint, strengthens scientific capabilities, and drives high-quality outcomes for clients worldwide.
For the global NRI community, particularly those in healthcare, research, and STEM fields, Dr. Tharmaratnam’s journey is a beacon of perseverance, expertise, and impact. A UK-trained physician of Indian origin specializing in anesthesia and critical care, he has navigated complex regulatory landscapes, built market-leading operations across Asia-Pacific, and now steers Novotech toward greater global influence from its new headquarters in Singapore. His story underscores the NRI ethos: turning rigorous training, cultural adaptability, and unwavering commitment into leadership that accelerates medical breakthroughs.
Early Foundations: Medical Training and Entry into Clinical Research
Dr. Tharmaratnam’s path began with a strong medical foundation. Trained in the UK, he specialized in anesthesia and critical care, earning credentials including fellowship with the Royal College of Anaesthetists. This clinical background—rooted in hands-on patient care during high-pressure scenarios—provided an invaluable perspective on the real-world implications of drug development and trial design.
Transitioning from bedside medicine to the broader arena of clinical research, he joined Quintiles, then a rising global CRO powerhouse, where he would spend over two decades shaping the industry’s Asia-Pacific landscape. His early roles honed skills in operational excellence, regulatory compliance, and cross-cultural team leadership—essential in a field where trials span continents and diverse patient populations.
(Suggested visual: Career timeline graphic spanning from UK medical training → Quintiles/IQVIA tenure (1990s–2020) → Novotech Chairman (2021) → CEO appointment (January 2026). Include icons for anesthesia/critical care, Asia-Pacific growth, and global CRO symbols.)
Quintiles/IQVIA Era: Building Asia-Pacific Leadership
Dr. Tharmaratnam’s 23 years at Quintiles and IQVIA represent one of the most influential chapters in Asia’s CRO evolution. Joining during a period of rapid globalization in clinical trials, he rose to become Head of Asia and Japan—a position he held for a decade until 2020. This role placed him on the global executive committees of both companies, where he guided strategic decisions amid major milestones:
- Quintiles’ NYSE public offering in 2013.
- The landmark merger of Quintiles and IMS Health to form IQVIA in 2016.
Under his leadership, Quintiles/IQVIA solidified its position as the market leader in Asia, earning accolades like “Best CRO in Asia” multiple times. He championed the region’s potential: faster patient recruitment, diverse populations for robust data, cost efficiencies, and regulatory advancements in markets like China, Japan, South Korea, and Southeast Asia.
His tenure coincided with the Asia-Pacific’s emergence as a clinical trials hub. Dr. Tharmaratnam navigated challenges like varying regulatory frameworks, cultural nuances in patient engagement, and infrastructure gaps—transforming them into competitive advantages. In 2015, he was honored as “Asian Male Executive of the Year” at the BioPharma Asia Industry Awards, recognizing his role in elevating the region’s stature.
Transition to Novotech: From Chairman to CEO
In December 2020, Dr. Tharmaratnam was appointed Chairman of Novotech Health Holdings, bringing his deep expertise to a CRO already gaining momentum in biotech-focused trials. Novotech, with roots in Australia and a strong Asia-Pacific presence, had built a reputation for agile, high-quality delivery in early- to late-phase studies.
By January 8, 2026, the company announced his elevation to CEO and Chairman, a seamless leadership transition reflecting Novotech’s international ambitions. Based in Singapore—the new global headquarters—Dr. Tharmaratnam is positioned to lead expansion, enhance scientific advisory services, and leverage technology for faster, more efficient trials. His appointment aligns with Novotech’s growth trajectory: recent white papers on early-phase oncology (December 2025), support for groundbreaking approvals like anlotinib combination therapy (August 2025), and insights into live biotherapeutics and other emerging areas.
Under his guidance, Novotech continues to prioritize biotech sponsors, offering end-to-end services from strategy to execution, with a focus on Asia-Pacific’s accelerating role in global pipelines.
(Suggested visual: Professional photo of Dr. Anand Tharmaratnam in a leadership setting at Novotech’s Singapore headquarters or a modern CRO environment; pair with a world map highlighting Novotech’s trial sites across Asia-Pacific, Australia, USA, and Europe.)
Breakthroughs and Industry Impact: Driving Global Clinical Trials Forward
Dr. Tharmaratnam’s career has coincided with—and helped shape—the CRO industry’s maturation. Key impacts include:
- Pioneering Asia-Pacific growth, enabling faster enrollment in diverse populations critical for oncology, rare diseases, and infectious diseases trials.
- Advocating for patient-centric approaches, regulatory harmonization, and technology integration (e.g., digital tools for data quality and timelines).
- Positioning Novotech as a preferred partner for biotech innovators, with expertise in complex, adaptive designs and early-phase oncology.
In 2025–2026, Novotech’s contributions—such as white papers guiding sponsors on risk management and execution—reflect Dr. Tharmaratnam’s forward-looking vision. His leadership emphasizes quality, speed, and global collaboration, vital as biotech pipelines expand amid rising R&D investments.
Challenges Overcome: Perseverance in a Demanding Field
The CRO sector demands resilience: navigating economic cycles, regulatory shifts (e.g., post-COVID adaptations), geopolitical complexities, and intense competition. As an NRI leader in a Western-dominated industry, Dr. Tharmaratnam faced cultural and operational barriers in building Asia-Pacific dominance.
Yet his perseverance shone through—balancing clinical rigor with business strategy, fostering inclusive teams, and turning regional challenges into global strengths. His journey inspires NRIs facing similar hurdles: excellence and adaptability overcome biases and obstacles.
Philosophy: Expertise, Collaboration, and Purpose-Driven Leadership
Dr. Tharmaratnam’s approach centers on scientific integrity, operational excellence, and client-centric innovation. He views CROs as enablers of breakthroughs: “Delivering high-quality outcomes for biotech clients worldwide” defines his 2026 mandate.
Quotes and principles from his career highlight:
- Emphasis on Asia-Pacific’s untapped potential for diverse, efficient trials.
- Commitment to strengthening capabilities amid global expansion.
- Belief in collaborative ecosystems—partnering with sponsors to accelerate therapies.
His philosophy blends medical empathy with strategic foresight, motivating teams to prioritize patient impact.
Diaspora Inspiration: An NRI Trailblazer in Healthcare Research
For Indian-origin professionals worldwide, Dr. Tharmaratnam exemplifies how heritage fuels global success. From UK training to Asia-Pacific leadership and now Singapore-based CEO, his path shows NRIs can lead transformative industries. He inspires perseverance in research, where long timelines demand sustained dedication.
15+ Lessons from Dr. Anand Tharmaratnam’s Journey
- Build Deep Expertise — Clinical roots provide unmatched insight into trials.
- Embrace Regional Opportunities — Asia-Pacific’s diversity accelerates innovation.
- Lead Through Transitions — Navigate mergers, IPOs, and leadership changes.
- Prioritize Quality — High standards ensure reliable outcomes.
- Foster Collaboration — Global success requires cross-cultural partnerships.
- Adapt to Change — Regulatory and tech shifts demand agility.
- Invest in Teams — Inclusive leadership drives excellence.
- Focus on Impact — Accelerate therapies that save lives.
- Persevere Long-Term — 30+ years yield sustained leadership.
- Leverage Heritage — NRI adaptability is a strength.
- Champion Emerging Markets — Unlock potential in Asia and beyond.
- Stay Forward-Looking — White papers and strategies guide the future.
- Balance Science and Business — Merge rigor with strategy.
- Give Back Through Mentorship — Elevate the next generation.
- Pursue Purpose — Align career with global health advancement.
- Celebrate Milestones — Awards and recognitions fuel momentum.
Outlook and Legacy: Shaping the Future of Clinical Research
As CEO in 2026, Dr. Tharmaratnam is poised to propel Novotech into its next era: deeper biotech partnerships, enhanced early-phase capabilities, and expanded global reach. His leadership promises accelerated timelines, better data, and more therapies reaching patients faster.
For the NRI diaspora, his story is motivational proof: With expertise, perseverance, and vision, one can rise to lead global healthcare innovation. Dr. Anand Tharmaratnam’s journey—from physician to CRO titan—reminds us that dedication in research not only builds careers but transforms lives worldwide.
About the Author Sreekanth is a US-based NRI journalist passionate about immigrant success stories, healthcare innovations, and inspirational narratives for the global Indian diaspora. Covering biotech, clinical research, and leadership journeys, he highlights paths like Dr. Tharmaratnam’s to empower aspiring professionals. Connect via nriglobe.com.
Latest NRI News & Global Updates:
Health, Wellness & Lifestyle for NRIs
https://nriglobe.com/health-wellness/
Latest NRI News & Global Updates
https://nriglobe.com/news/
Business & Finance News for NRIs
https://nriglobe.com/business/
Investment Guides for NRIs
https://nriglobe.com/investment/
Jobs & Career Opportunities for NRIs
https://nriglobe.com/jobs/
